[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05899556":3,"trial-entities:NCT05899556":81,"trial-summary:NCT05899556":84},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":15,"phases":21,"enrollment_info":22,"interventions":25,"primary_outcomes":26,"secondary_outcomes":33,"sex":34,"minimum_age":35,"maximum_age":15,"healthy_volunteers":36,"eligibility_criteria":37,"std_ages":47,"locations":50,"central_contacts":60,"overall_officials":66,"references":69,"see_also_links":80},"NCT05899556","83217345","Pinpointing the Factors Affecting Clinical Study Experiences of Pulmonary Fibrosis Patients","A Comprehensive View of Patient Experiences of Individuals Participating in Pulmonary Fibrosis Clinical Study","UNKNOWN","2026-07","2023-06","2023-06-12","2024-07","Power Life Sciences Inc.","INDUSTRY",null,"Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what research attributes affect the completion of these specific demographic groups.\n\nThis study will admit a wide range of data on the clinical trial experience of pulmonary fibrosis patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.\n\nIt will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future pulmonary fibrosis patients.",[18],"Pulmonary Fibrosis",[18],"OBSERVATIONAL",[],{"count":23,"type":24},500,"ESTIMATED",[],[27,30],{"measure":28,"timeFrame":29},"Number of pulmonary fibrosis patients who decide to participate in a clinical study","3 months",{"measure":31,"timeFrame":32},"Rate of patients who remain in an pulmonary fibrosis clinical study to completion","12 months",[],"ALL","18 Years",false,{"inclusion":38,"exclusion":42,"raw_text":46},[39,40,41],"Patient is at least 18 years of age","Diagnosis of pulmonary fibrosis","Ability to understand the study procedures, benefits and risks, and sign a written informed consent document.",[43,44,45],"Enrolled in another research study","Inability to provide written informed consent","Women of childbearing potential without a negative pregnancy test; or women who are lactating.","Inclusion Criteria:\n\n* Patient is at least 18 years of age\n* Diagnosis of pulmonary fibrosis\n* Ability to understand the study procedures, benefits and risks, and sign a written informed consent document.\n\nExclusion Criteria:\n\n* Enrolled in another research study\n* Inability to provide written informed consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.",[48,49],"ADULT","OLDER_ADULT",[51],{"facility":52,"city":53,"state":54,"zip":55,"country":56,"geoPoint":57},"Power Life Sciences","San Francisco","California","94107","United States",{"lat":58,"lon":59},37.77493,-122.41942,[61],{"name":62,"role":63,"phone":64,"email":65},"Michael B Gill","CONTACT","4159004227","bask@withpower.com",[67],{"name":62,"affiliation":13,"role":68},"STUDY_DIRECTOR",[70,74,77],{"pmid":71,"type":72,"citation":73},"28257817","BACKGROUND","Aiello M, Bertorelli G, Bocchino M, Chetta A, Fiore-Donati A, Fois A, Marinari S, Oggionni T, Polla B, Rosi E, Stanziola A, Varone F, Sanduzzi A. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2017 Jun;44:7-15. doi: 10.1016\u002Fj.pupt.2017.02.005. Epub 2017 Feb 28.",{"pmid":75,"type":72,"citation":76},"35001525","Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, Reiss AB. Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J. 2022 Feb;16(2):84-96. doi: 10.1111\u002Fcrj.13466. Epub 2022 Jan 10.",{"pmid":78,"type":72,"citation":79},"26020856","O'Riordan TG, Smith V, Raghu G. Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design. Chest. 2015 Oct;148(4):1083-1092. doi: 10.1378\u002Fchest.14-3218.",[],{"nct_id":4,"conditions":82,"biomarkers":83},[18],[],{"nct_id":4,"found":85,"summary":86,"prompt_version":96},true,{"design":87,"status":88,"heading":89,"summary":90,"follow_up":91,"word_count":92,"commitments":93,"compensation":94,"drugs_mentioned":95},"This is an observational study, meaning no interventions are given. It aims to enroll 500 participants to understand their experiences in clinical studies.","completed","Understanding Clinical Study Experiences for Pulmonary Fibrosis Patients","This study aims to understand what helps or hinders people with pulmonary fibrosis (a lung disease that causes scarring of the lungs) from joining or finishing clinical studies. It's an observational study, meaning you won't receive any new treatments. Instead, researchers will collect information about your experiences. They want to find out how many patients decide to join a study and how many complete it. This information will help improve future studies for people with pulmonary fibrosis. You can join if you are at least 18 years old and have a diagnosis of pulmonary fibrosis. The study plans to include 500 participants.","The study will measure patient participation at 3 months and completion rates at 12 months.",102,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]